Fifth Third Bancorp grew its position in shares of Boston Scientific Co. (NYSE:BSX) by 1.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 856,228 shares of the medical equipment provider’s stock after purchasing an additional 14,866 shares during the quarter. Fifth Third Bancorp’s holdings in Boston Scientific were worth $32,965,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in the company. FMR LLC boosted its stake in shares of Boston Scientific by 5.5% during the third quarter. FMR LLC now owns 165,239,463 shares of the medical equipment provider’s stock valued at $6,361,719,000 after purchasing an additional 8,617,011 shares in the last quarter. BlackRock Inc. boosted its stake in shares of Boston Scientific by 2.7% during the third quarter. BlackRock Inc. now owns 112,313,832 shares of the medical equipment provider’s stock valued at $4,324,083,000 after purchasing an additional 2,958,437 shares in the last quarter. Janus Henderson Group PLC boosted its stake in shares of Boston Scientific by 0.7% during the second quarter. Janus Henderson Group PLC now owns 41,739,459 shares of the medical equipment provider’s stock valued at $1,364,885,000 after purchasing an additional 273,848 shares in the last quarter. Standard Life Aberdeen plc boosted its stake in shares of Boston Scientific by 1.3% during the second quarter. Standard Life Aberdeen plc now owns 13,998,353 shares of the medical equipment provider’s stock valued at $457,817,000 after purchasing an additional 178,939 shares in the last quarter. Finally, Putnam Investments LLC boosted its stake in shares of Boston Scientific by 14.4% during the second quarter. Putnam Investments LLC now owns 10,003,513 shares of the medical equipment provider’s stock valued at $327,115,000 after purchasing an additional 1,258,287 shares in the last quarter. 90.85% of the stock is currently owned by hedge funds and other institutional investors.

BSX has been the topic of a number of recent research reports. Raymond James lifted their price target on Boston Scientific from $40.00 to $41.00 and gave the company a “strong-buy” rating in a research note on Tuesday, September 4th. Barclays initiated coverage on Boston Scientific in a research note on Monday, October 15th. They set an “overweight” rating and a $43.00 price target on the stock. Guggenheim lifted their price target on Boston Scientific to $45.00 and gave the company a “buy” rating in a research note on Friday, November 16th. Oppenheimer reissued a “hold” rating on shares of Boston Scientific in a research note on Wednesday, November 21st. Finally, Jefferies Financial Group raised Boston Scientific from a “hold” rating to a “buy” rating and lifted their price target for the company from $34.00 to $42.00 in a research note on Tuesday, September 4th. One research analyst has rated the stock with a sell rating, three have given a hold rating, twenty have assigned a buy rating and three have issued a strong buy rating to the company’s stock. Boston Scientific has a consensus rating of “Buy” and a consensus target price of $39.54.

Shares of BSX opened at $35.48 on Friday. Boston Scientific Co. has a 1 year low of $24.79 and a 1 year high of $39.44. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.58. The stock has a market cap of $50.88 billion, a PE ratio of 28.16, a P/E/G ratio of 2.42 and a beta of 0.70.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, October 24th. The medical equipment provider reported $0.35 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.34 by $0.01. The business had revenue of $2.39 billion during the quarter, compared to the consensus estimate of $2.40 billion. Boston Scientific had a return on equity of 26.44% and a net margin of 6.93%. The firm’s revenue for the quarter was up 7.7% on a year-over-year basis. During the same period in the previous year, the company posted $0.31 earnings per share. On average, research analysts anticipate that Boston Scientific Co. will post 1.39 EPS for the current fiscal year.

In other Boston Scientific news, SVP Wendy Carruthers sold 1,500 shares of Boston Scientific stock in a transaction that occurred on Friday, November 2nd. The stock was sold at an average price of $36.64, for a total value of $54,960.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP John Bradley Sorenson sold 10,000 shares of Boston Scientific stock in a transaction that occurred on Monday, September 10th. The stock was sold at an average price of $35.86, for a total value of $358,600.00. Following the completion of the sale, the senior vice president now owns 44,636 shares of the company’s stock, valued at $1,600,646.96. The disclosure for this sale can be found here. Over the last quarter, insiders sold 472,827 shares of company stock valued at $17,554,528. 0.73% of the stock is currently owned by corporate insiders.

WARNING: This piece of content was reported by Daily Political and is owned by of Daily Political. If you are reading this piece of content on another website, it was stolen and reposted in violation of United States and international copyright & trademark laws. The correct version of this piece of content can be read at https://www.dailypolitical.com/2018/12/08/fifth-third-bancorp-purchases-14866-shares-of-boston-scientific-co-bsx.html.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

Recommended Story: How is an ETF different from a mutual fund?

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX).

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.